Family medicine clinicians prescribing GLP-1 receptor agonists for obesity must understand differential ketoacidosis risk between agents, as euglycemic diabetic ketoacidosis has been documented with semaglutide in non-diabetic patients and represents a potentially life-threatening complication requiring heightened clinical vigilance. The comparative safety profile between semaglutide and tirzepatide-particularly tirzepatide’s dual GIP/GLP-1 mechanism-may influence risk stratification and agent selection in vulnerable populations such as those with eating disorders, acute illness, or metabolic stress. Recognizing these differences enables more informed shared decision-making and appropriate monitoring protocols when initiating or managing these increasingly common obesity therapies in primary care.
A retrospective cohort study compared the incidence of diabetic ketoacidosis (DKA) and euglycemic ketoacidosis (euDKA) in non-diabetic patients treated with semaglutide versus tirzepatide for obesity management. The study examined administrative claims data and electronic health records across a large US healthcare system, enrolling non-diabetic adults who initiated either semaglutide or tirzepatide between 2021 and 2023. Patient cohorts were matched on baseline characteristics including age, sex, BMI, comorbidities, and medication use. The primary outcome was the composite incidence of DKA or euDKA during treatment or within 30 days of discontinuation, with secondary outcomes examining hospitalizations, emergency department visits, and serious adverse events related to ketoacidosis.
The semaglutide cohort included 4,827 patients with 8,432 person-years of follow-up, while the tirzepatide cohort comprised 3,614 patients with 6,218 person-years of follow-up. DKA or euDKA occurred in 12 semaglutide-treated patients (1.4 per 1,000 person-years) compared with 3 tirzepatide-treated patients (0.5 per 1,000 person-years), yielding an adjusted hazard ratio of 2.8 (95% CI 0.8 to 9.7). Hospitalizations for metabolic acidosis were numerically higher in the semaglutide group, though differences did not reach statistical significance. No patient deaths from ketoacidosis were documented in either cohort. The median time to ketoacidosis onset was 4.2 months in semaglutide users and 5.8 months in tirzepatide users.
For prescribers, while the absolute risk of ketoacidosis in non-diabetic patients remains low with both agents, the numerical difference observed warrants heightened clinical awareness and patient counseling about warning signs including nausea, vomiting, dyspnea, and abdominal pain. Baseline metabol
Clinical Takeaway:
Both semaglutide and tirzepatide carry a documented risk of ketoacidosis in non-diabetic patients, though this complication remains uncommon when used appropriately for obesity management. The risk appears related to rapid weight loss, reduced caloric intake, and possible direct effects on glucagon suppression rather than to diabetes status alone. Baseline metabolic screening and patient education about warning signs such as persistent nausea, abdominal pain, or unusual fatigue are essential before initiating therapy. When counseling patients, clearly explain that while ketoacidosis is rare, seeking immediate care for severe abdominal symptoms or shortness of breath during treatment is critical, and that temporary dose reduction or discontinuation may be necessary during periods of acute illness or marked dietary restriction.
“What this research underscores is that we cannot treat GLP-1 and dual GIP/GLP-1 receptor agonists as interchangeable agents, particularly when it comes to euglycemic diabetic ketoacidosis risk in our non-diabetic populations. The mechanistic differences between these drug classes, especially tirzepatide’s additional GIP receptor activity and its effects on glucagon suppression, create distinct safety profiles that demand our clinical attention. Clinically, this means I’m counseling non-diabetic patients on semaglutide about DKA warning signs-nausea, fatigue, unusual breathing patterns-while maintaining heightened vigilance with tirzepatide users, even though absolute risk remains rare. The takeaway for my practice is straightforward: drug selection matters beyond efficacy metrics, and informed consent conversations need to reflect these pharmacodynamic nuances rather than lumping these agents together as a drug
? Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
Can I get diabetic ketoacidosis if I don’t have diabetes and use semaglutide or tirzepatide?
Yes, there is a rare but serious risk of ketoacidosis even in non-diabetic patients taking these medications. This risk appears to be higher with tirzepatide compared to semaglutide, though both GLP-1 medications carry this potential complication.
What symptoms should I watch for that might indicate ketoacidosis?
Watch for severe nausea, vomiting, abdominal pain, unusual fatigue, difficulty breathing, or fruity-smelling breath. These symptoms require immediate emergency medical attention and blood work to check your acid-base status.
Why does ketoacidosis happen with GLP-1 medications in people without diabetes?
These medications can lower insulin levels and increase glucagon, which shifts your body toward burning fat rapidly and producing ketones. In rare cases, ketone levels can rise to dangerous amounts even without high blood sugar.
Is tirzepatide riskier than semaglutide for ketoacidosis?
Current evidence suggests tirzepatide may carry a higher ketoacidosis risk than semaglutide because it affects both GLP-1 and GIP pathways, which can lower insulin more substantially. Your doctor should discuss this difference when choosing between these medications.
Can I prevent ketoacidosis while taking these medications?
Stay well hydrated, eat regular meals to maintain adequate carbohydrate intake, and avoid prolonged fasting or crash diets while on GLP-1 therapy. Report any signs of illness, severe nausea, or vomiting to your doctor immediately.
Should I get blood tests before starting semaglutide or tirzepatide?
Yes, baseline blood work including kidney function, liver function, and metabolic panel is standard before starting these medications. Your doctor uses this information to monitor for complications including any metabolic changes.
How often will my doctor check on me once I start GLP-1 therapy for obesity?
You should have regular follow-up visits, especially in the first few weeks after starting or increasing your dose. Your doctor will monitor your symptoms, weight loss, and any signs of side effects or metabolic concerns.
What happens if I develop ketoacidosis while on these medications?
You need immediate emergency care with IV fluids and electrolyte replacement to correct the acid-base imbalance. You will likely need to stop the GLP-1 medication and your doctor will identify what triggered the ketoacidosis to prevent it from happening again.
Are there warning signs specific to non-diabetic ketoacidosis I should know about?
Non-diabetic ketoacidosis often presents without high blood sugar, so you might not notice classic diabetes symptoms like excessive thirst or urination. Severe nausea, vomiting, and abdominal pain combined with shortness of breath are the key warning signs to take seriously.
Should I ask my doctor about the choice between semaglutide and tirzepatide based on ketoacidosis risk?
Yes, this is an important conversation to have with your doctor before starting therapy. Your individual risk factors, kidney function, and other medications should all factor into which GLP-1 medication is safest for you.
